Stem cell therapies without tears
By Editorial,
The New Scientist
| 06. 15. 2007
Expect to hear a familiar refrain over the coming days: "There's no need for embryonic stem cells." It is the likely response of those who oppose any interference with human embryos to the exciting news that adult mouse cells can be reprogrammed to an embryonic state by boosting the activity of just four critical genes (see "From adult to embryo").
There are good reasons to question the campaigners' claims. The trick has yet to be achieved in human cells. Even if that can be done, it will still be necessary to show that the reprogrammed cells have the same ability as embryonic cells to develop into different tissues. But let's assume that all these issues can one day be resolved. Would the need for cells isolated from embryos disappear?
The eventual goal of the latest work is to derive stem cell lines genetically matched to patients, from which to grow replacement cells and tissues. Transferring the nucleus of an adult cell into an egg can send it back to an embryonic state, but how such cloning works remains mysterious. Reprogramming...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...